Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced ...

Regeneron (NASDAQ: REGN ) released a strong financial report for the third quarter. We saw double the success in exceeding the total earnings per share and quarterly revenue. However, the market reacted to this report with a 9.2% drop in the quote on the dayI am a qualified economist specializing in economic theory and I have been investing and trading since 2005. Since 2018, I have been investing in US equities. Until 2022, I was part of TopStepTrader, having passed the combine for a funded trader. I am a ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum. Shares of Regeneron (NASDAQ: REGN ) lost nearly a third of their value ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Ryan Crowe - SVP, IR and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and CEO George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - EVP, Commercial Chris Fenimore - SVP, Finance and CFO Conference Call Participants Taylor Hanley - JPMorgan Tyler Van Buren - TD Cowen Brian Abrahams - RBC Capital Marke ...

Regeneron (REGN) reported $3.72 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 10.7%. EPS of $12.46 for the same period compares to $11.59 a year ago.The reported revenue represents a surprise of +1.31% over the Zacks Consensus Estimate of $3.67 billion. With the consensus EPS estimate being $11.75, the EPS surprise was +6.04%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determ ...

Regeneron Pharmaceuticals, Inc. (REGN) reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea HD sales, profits from blockbuster asthma drug Dupixent and oncology drug Libtayo. The top line beat the Zacks Consensus Estimate of $3.67 billion.Higher revenues drove the bottom line as well. Adjusted earnings per share (EPS) of $12.46 beat the Zacks Consensus Estimate of $11.75 and were up 8% from the yea ...

Regeneron (REGN) came out with quarterly earnings of $12.46 per share, beating the Zacks Consensus Estimate of $11.75 per share. This compares to earnings of $11.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.04%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $10.57 per share when it actually produced earnings of $11.56, delivering a surprise of 9.37%.Over the last four quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York ...

Exhibit 99.1 REGENERON Press Release Regeneron Reports Third Quarter 2024 Financial and Operating Results • Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023 • Third quarter 2024 Dupixent global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023 • Third quarter 2024 U.S. net sales for EYLEA HD and EYLEA increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD • Third quarter 2024 Libtayo global net s ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 23% to $3.82 billion versus third quarter 2023Third quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HDThird quarter 2024 Libtayo® global net sales increased 24% to $289 million versus third quarter 2023Third quarter 2024 GAAP diluted EPS increased 30% to ...